Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(04): 414-416
DOI: 10.4103/wjnm.WJNM_15_20
Case Report

Interpreting discordance on dual-tracer positron emission tomography–computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma

Ashwini Kalshetty
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sandip Basu
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Second primary malignancies (SPMs) are known to be associated with neuroendocrine tumors (NETs). The association necessitates a careful assessment of the dual-tracer positron emission tomography–computed tomography (PET-CT) imaging findings to identify these malignancies earlier. Such early diagnosis can provide incremental benefit for screening these SPMs apart from their known applications in the management of NETs. A case of incidentally detected metachronous triple-negative breast carcinoma on dual-tracer PET-CT imaging is presented using 18fluoro-2-deoxy-D-glucose (FDG) and 68Ga-DOTATATE that showed a high uptake on FDG but no uptake on somatostatin receptor-based imaging.

Keywords

68Ga-DOTATATE - dual-tracer positron emission tomography–computed tomography - fluoro-2-deoxy-D-glucose positron emission tomography–computed tomography - metastatic neuroendocrine tumors - triple-negative breast carcinoma

Financial support and sponsorship

Nil.




Publication History

Received: 21 March 2020

Accepted: 31 March 2020

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Genus T, Bouvier C, Wong K, Srirajaskanthan R, Rous B, Talbot D, et al. Metachronous primary cancers in neuroendocrine tumour patients. EJEA 2017;52. p. 13. doi: 10.1530/endoabs.52.P13. Available from: https://doi.org/10.1530/endoabs. 52.P13. [Last accessed on 2020 Mar 21].
  • 2 Kharmate G, Rajput PS, Lin YC, Kumar U. Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells. Cancer Cell Int 2013;13:93.
  • 3 Basu S, Abhyankar A. The use of 99mTc-HYNIC-TOC and 18F-FDG PET/CT in the evaluation of duodenal neuroendocrine tumor with atypical and extensive metastasis responding dramatically to a single fraction of PRRT with 177Lu-DOTATATE. J Nucl Med Technol 2014;42:296-8.
  • 4 Elgeti F, Amthauer H, Denecke T, Steffen I, Heuck F, Stelter L, et al. Incidental detection of breast cancer by 68Ga-DOTATOC-PET/CT in women suffering from neuroendocrine tumours. Nuklearmed 2008;47:261-5.
  • 5 Dalm SU, Haeck J, Doeswijk GN, de Blois E, de Jong M, van Deurzen CH. SSTR-mediated imaging in breast cancer: Is there a role for radiolabeled somatostatin receptor antagonists? J Nucl Med 2017;58:1609-14.
  • 6 Chereau E, Durand L, Frati A, Prignon A, Talbot JN, Rouzier R. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. Anticancer Res 2013;33:3015-9.